Opioids

The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose. The agency's target action date is November 12. The company resubmitted the application in May...

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose. "Based on FDA feedback received during our Type A meeting in April, we have resubmitted...

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of Dsuvia (sufentanil sublingual tablet, SST) 30 mcg for the...

Baudax Bio Inc (NASDAQ: BXRX) has announced the online publication of Phase 3b study data highlighting the safety and efficacy of preoperative Anjeso (meloxicam) injection in patients undergoing unilateral total knee arthroplasty (TKA) when used within a multimodal analgesic...

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid overdose. Type A meeting with the FDA was concluded. The company believes the...

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain...

New York Governor Andrew Cuomo on Thursday announced the state has filed civil charges against Johnson & Johnson (NYSE: JNJ), accusing it of insurance fraud in connection with understating the risks posed by opioid drugs to doctors and elderly patients.  What Happened: The...

Mallinckrodt PLC (NYSE: MNK) shares are ripping higher Tuesday after the company announced a global opioid settlement agreement that limits its payout to $1.6 billion and it aslo reported better-than-expected fourth-quarter results. Opioid Settlement Clinched, Generics Business To File For Chapter...

It appears more and more likely a case against opioid manufacturers and distributors will proceed to trial in New York state, keeping Bank of America bearish on the companies despite recent performance. The recent denial of a motion to delay the case — which the state brought against the...

Shares of midcap biopharma Nektar Therapeutics (NASDAQ: NKTR) are retreating sharply following a negative verdict handed down by FDA staffers for its opioid pain drug. FDA Panel Flashes The Red Signal San Francisco-based Nektar said a joint sitting of the Anesthetic and Analgesic Drug Products...

A Massachusetts company took the grand prize Dec. 12 in the Trump administration's nearly yearlong challenge to the private sector to develop efficient, nonintrusive scanning technologies to intercept dangerous illicit drugs in international mail. IDSS won $500,000 for its detection technology,...

The health care sector has shed its laggard ways as highlighted by the Health Care Select Sector SPDR (NYSE: XLV). The largest exchange traded fund dedicated to the S&P 500's second-largest sector weight is up nearly 7% this month and is flirting with a year-to-date gain of 15%. While...

McKesson Corporation (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AmerisourceBergen Corp. (NYSE: ABC) have reached 11th-hour settlements to avert opioid trials in Ohio, The Wall Street Journal reported.  Details were expected to emerge early...

Johnson & Johnson (NYSE: JNJ) shares traded higher by 2% on Wednesday on reports of potential opioid settlement negotiations, but at least a handful of large option traders aren’t optimistic that the J&J rally will last. The Trades On Wednesday morning, Benzinga Pro subscribers were...

Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces. The Analysts Morgan Stanley’s...